Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine (NCT07129889) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine
China180 participantsStarted 2025-12-02
Plain-language summary
0.01% atropine is an effective measure for controlling myopia in children and is widely used in Asia for this purpose. However, there is a phenomenon of rebound and worsening of myopia after discontinuation of the medication. Auricular acupressure (AA) is gaining attention as a complementary therapy for myopia control. However, there is a lack of rigorous studies evaluating the effectiveness of AA in reducing rebound after discontinuing atropine eye drops in myopic children. Our study aims to assess the efficacy and safety of AA in reducing rebound after discontinuing atropine in myopic children.
Who can participate
Age range6 Years – 12 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Meets the diagnostic criteria for myopia;
✓. Age 6-12 years, no gender restrictions;
✓. Single or bilateral spherical refractive error between -1.00 and -4.00 D (astigmatism ≤ 1.50 D, anisometropia ≤ 1.50 D);
✓. Best-corrected visual acuity in both eyes of 0.20 logMAR or higher;
✓. Intraocular pressure (IOP) less than 21 mmHg;
✓. Informed consent form signed by a guardian, voluntarily participating.
Exclusion criteria
✕. Eye conditions other than refractive errors (e.g., strabismus, amblyopia, keratitis, glaucoma, cataracts, retinal detachment, etc.);
✕. Patients with systemic conditions that may affect refractive development (e.g., Down syndrome, Marfan syndrome);
✕. Patients with uncontrolled systemic diseases or debilitating conditions, immune deficiencies, or severe primary diseases of the cardiovascular, hepatic, renal, or hematopoietic systems, immune system disorders, or psychiatric conditions;
What they're measuring
1
Myopia Rebound Rate
Timeframe: Statistical analysis was performed at 3 months and 6 months after dose reduction, and at 1 month, 3 months, and 6 months after discontinuation of medication.
✕. Patients with a history of allergies or hypersensitivity to multiple medications;
✕. Patients who have undergone ocular surgery within the past 4 weeks prior to screening;
✕. Patients planning to undergo ocular surgery within one year of enrollment;
✕. Patients who have participated in other drug clinical trials within the past 3 months prior to screening; Patients who are unable to cooperate with treatment, observation, and assessment.